Indomethacin Morpholinylamide

Indomethacin Morpholinylamide

SCHEMBL8314320

COc1ccc2c(c1)c(CC(=O)N1CCOCC1)c(C)n2C(=O)c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 8/20 1.00
MEN1 O00255 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2C9 P11712 2/20 1.00
PMP22 Q01453 2/20 1.00
KMT2A Q03164 2/20 1.00
GMNN O75496 1/20 1.00
CYP3A4 P08684 1/20 1.00
PKM P14618 1/20 1.00
TSHR P16473 1/20 1.00
NFKB1 P19838 1/20 1.00
CYP2C19 P33261 1/20 1.00
BLM P54132 1/20 1.00
CNR1 P21554 6/20 0.82
LMNA P02545 2/20 0.77
NPSR1 Q6W5P4 2/20 0.77
PTGS2 P35354 8/20 0.73
AKR1C3 P42330 2/20 0.71
PTGS1 P23219 2/20 0.71
KDM4E B2RXH2 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indomethacin Morpholinylamide SCHEMBL29358919 1.00 CNR2 (1.00) CNR2MEN1CYP1A2CYP2C9PMP22
SCHEMBL16870401 0.93 CNR2 (0.86) CNR2MEN1CYP1A2CYP2C9PMP22
SCHEMBL15934125 0.90 LMNA (0.82) CNR2MEN1CYP1A2CYP2C9PMP22
SCHEMBL13286994 0.90 LMNA (0.85) CNR2MEN1CYP1A2CYP2C9PMP22
SCHEMBL861080 0.90 LMNA (0.82) CNR2MEN1CYP1A2CYP2C9PMP22
SCHEMBL13286940 0.89 CNR2 (0.80) CNR2MEN1CYP1A2CYP2C9PMP22
SCHEMBL3842689 0.88 CNR2 (0.78) CNR2MEN1CYP1A2CYP2C9PMP22
SCHEMBL15932300 0.87 LMNA (0.78) CNR2MEN1CYP1A2CYP2C9PMP22
SCHEMBL6361111 0.87 PTGS2 (0.81) CNR2MEN1CYP1A2CYP2C9PMP22
Indomethacin SCHEMBL27537912 0.86 PTGS2 (0.78) CNR2MEN1CYP1A2CYP2C9PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150183737-A1 COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2015-07-02 US disclosed
WO-2014015341-A2 COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION VANDERBILT UNIVERSITY (US) 2014-01-23 WO disclosed
WO-2004078261-A1 CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150183737-A1 COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION CNR2, FAAH2, FAAH CNR2 1/4885MEN1 4838/4885CYP1A2 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.